Experimental Obesity Drug to Show Muscle-Sparing Data
Adults managing weight should know these early findings come from mouse studies and the drug is not yet approved for use in people.
Updated on Nov. 4, 2026 in Weight Loss
Sironax, a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, has had two abstracts on its experimental obesity drug SIR4156 selected for poster presentation at ObesityWeek 2026 on November 14. The company is also advancing enrollment in its Phase 2 FORGE-LM obesity trial, and SIR4156 has not yet been approved by any regulatory authority.
Why it matters
Obesity treatments are increasingly judged not only on how much weight they remove but on what kind of tissue is lost, since preserving lean muscle and reducing metabolically harmful fat are key goals for people managing weight over the long term. Because SIR4156 is still early in development, these presentations offer a first look at preclinical data rather than evidence of how it will perform in people.
The presented findings come from preclinical mouse models, including diet-induced obese (DIO) mice, and a weight-of-evidence carcinogenicity risk assessment. Because these are animal and preliminary data, they cannot yet confirm how SIR4156 would behave in people.
The players
Sironax
A global clinical-stage biotechnology company headquartered in Waltham, Massachusetts, developing SIR4156 as a treatment for obesity and metabolic dysfunction.
Fierce Biotech
A biotechnology trade publication that named Sironax to its 2026 Fierce 15 list.
The details
SIR4156 is an orally active allosteric activator of NAMPT, an enzyme involved in producing NAD+, a molecule central to cellular energy metabolism. The developer's goal is to restore NAD+ balance and support how cells use energy. In multiple preclinical models, the compound showed preferential fat loss, preservation of lean mass, reduced muscle atrophy, and improved physical performance, though these results come from animals and may not carry over to humans.
Timeline
November 14, 2026, 7:30-8:30 p.m. ET: Two SIR4156 abstracts scheduled for poster presentation in Exhibit Hall BCD.
November 14-17, 2026: ObesityWeek 2026 Obesity Society annual meeting.
Health Landscape
Most obesity drugs in use today work mainly by reducing body weight, and muscle loss during weight reduction is a recognized concern. Sironax's NAMPT-activator approach is one of several newer strategies aimed at improving the quality of weight loss, though it remains preclinical.
If you are managing weight, this early research highlights that the type of weight lost, including muscle versus fat, is becoming a focus of new treatments. Because SIR4156 is not yet approved or proven in people, it is worth discussing any interest in emerging therapies with your doctor rather than assuming a new option will be available.
The takeaway
Early preclinical data suggest some obesity treatments in development aim to protect lean muscle while reducing fat, but these findings are not yet proven in humans. If weight management is a current goal, a conversation with your physician about evidence-based options is the most practical next step.
What happens next
Sironax is advancing enrollment in its Phase 2 FORGE-LM trial of SIR4156, and the company's ObesityWeek poster presentations are scheduled for November 14, 2026.
Further reading
Explore more on Weight Loss research and treatment developments across the United States.
